Alexion is AstraZeneca’s Rare Disease unit, focused on developing and delivering therapies for conditions with high unmet need, particularly those involving complement system dysregulation and select metabolic/hematologic disorders. The portfolio includes Soliris (eculizumab) and Ultomiris (ravulizu